Related by context. All words. (Click for frequent words.) 79 orally administered inhibitor 79 refractory chronic lymphocytic 79 oral prodrug 78 forodesine 78 targeted radiotherapeutic 77 generation purine nucleoside 77 Personalized Immunotherapy 77 cutaneous T 76 multi kinase inhibitor 76 Phase #b/#a clinical 76 PDE4 inhibitor 76 dasatinib Sprycel ® 76 AAG geldanamycin analog 76 CYT# potent vascular disrupting 76 non nucleoside inhibitor 76 oral proteasome inhibitor 76 methylnaltrexone bromide 76 Panzem R 75 receptor tyrosine kinase inhibitor 75 JAK1 75 histone deacetylase HDAC inhibitor 75 molecular imaging radiopharmaceutical 75 IMiDs R 75 lintuzumab SGN 75 novel histone deacetylase 75 virus HCV protease inhibitor 75 intranasal formulation 75 cell lymphoma CTCL 75 VEGFR2 inhibitor 74 novel VDA molecule 74 IAP inhibitor 74 Solazed TM 74 oral ghrelin agonist 74 PEGylated Fab fragment 74 hormone LHRH antagonist 74 XL# anticancer compounds 74 ALN TTR 74 MAGE A3 ASCI 74 oral nucleoside analogue 74 systemic RNAi therapeutic 74 CDK cyclin dependent 74 pan histone deacetylase 74 CEQ# 74 Omacetaxine 74 peripherally acting 74 Romidepsin 74 TBC# 74 TELINTRA 74 investigational pharmacologically unique 74 ALN PCS 74 FOLOTYN ® 74 systemic anaplastic large 74 AEG# 74 modified glutathione analog 74 metaglidasen 73 IMiDs ® 73 Familial Adenomatous Polyposis FAP 73 investigational humanized monoclonal antibody 73 CYC# 73 PDX pralatrexate 73 radiation sensitizer 73 sapropterin dihydrochloride 73 Annamycin 73 proteasome inhibitor 73 selective kinase inhibitor 73 mGluR5 negative 73 5 HT3 antagonist 73 MT# MEDI 73 Cloretazine ® 73 OMNARIS HFA 73 OMP #R# 73 JAK2 Inhibitor 73 Factor VIIa 73 IMPDH inhibitor 73 polymerase inhibitor 73 Initiates Phase II 73 Hsp# Inhibitor 73 liposomal formulation 73 IL# PE#QQR 73 ADP receptor antagonist 73 R roscovitine CDK cyclin 73 orally bioavailable 73 PANVAC VF 73 cetuximab Erbitux R 73 selective androgen receptor modulator 73 selective antagonist 73 Alfacell proprietary ribonuclease 73 small molecule Hedgehog 73 Zenvia ™ 73 ALN TTR# 73 vapreotide acetate 73 alvespimycin 73 GVAX ® 72 selective immunoproteasome inhibitor 72 HSP# inhibitor 72 5 FU leucovorin 72 Aflibercept 72 RNAi Therapeutic 72 Completes Patient Enrollment 72 LHRH antagonist 72 humanized anti 72 platinum chemotherapeutic 72 leukemia AML 72 HQK 72 FOLFOX6 chemotherapy regimen 72 Ozarelix 72 2 methoxyestradiol 72 highly selective inhibitor 72 pan HDAC inhibitor 72 Sudhir Agrawal D.Phil 72 leading oral taxane 72 Orally administered 72 lenalidomide Revlimid R 72 DNA methyltransferase inhibitors 72 autologous cellular immunotherapy 72 mertansine 72 CYP#A# CYP#D# 72 Zemiva TM 72 5 HT2A inverse 72 Initiates Enrollment 72 evaluating satraplatin 72 selective modulator 72 triggers apoptosis programmed 72 Receives Orphan Drug Designation 72 Peginterferon alfa 2b 72 alpha folate receptor 72 Cutaneous T 72 investigational oral inhibitor 72 Cannabinor 72 Presents Preclinical Data 72 developing Zerenex ferric 72 Panzem R NCD 72 Bezielle 72 oncolytic virus therapies 72 ALN HPN 72 investigational pan BCR 72 LymphoStat B TM 72 sorafenib tablets 72 oral beclomethasone dipropionate 72 TELINTRA R 72 Epothilone D 72 dasatinib Sprycel 72 candidate deforolimus 72 IAP inhibitors 71 dependent kinase inhibitor 71 kidney urologic 71 thalidomide Thalomid 71 lexidronam injection 71 PEGylated anti 71 TLK# 71 PKC# 71 essential thrombocythemia ET 71 mTOR inhibitor 71 Investigational Oral 71 JAK2 inhibitor 71 allosteric modulator NAM 71 investigational immunotherapy 71 vinca alkaloid 71 antibody MAb 71 immunotherapeutic agent 71 Aurora kinase 71 SinuNase TM 71 SPRYCEL ® 71 NU# direct 71 Epratuzumab 71 diarrhea predominant irritable 71 CB2 selective receptor agonist 71 forodesine hydrochloride 71 huC# DM4 71 Luteinizing Hormone Releasing Hormone 71 alkylating agent 71 PI3K/Akt pathway inhibitor 71 developing Bicifadine serotonin 71 TO AVOID PREGNANCY WHILE 71 FUSILEV enhances 71 accumulate preferentially 71 sodium glucose cotransporter 71 Tezampanel 71 Panzem NCD 71 VitiGam 71 hypereosinophilic syndrome 71 pralatrexate injection folate analogue 71 MEK inhibitor 71 myelofibrosis polycythemia vera 71 class anticancer quinolone 71 Lenocta TM 71 candidates Azedra TM 71 histone deacetylase inhibitor 71 Xanafide 71 refractory cutaneous T 71 TNF Tumor Necrosis Factor 71 brand ciclesonide HFA 71 polysaccharide polymer 71 ENMD # 71 MTP inhibitor 71 delivers fluocinolone acetonide FA 71 Iluvien ® 71 chemosensitizer 71 signal transduction inhibitor 71 Forodesine 71 TRIOLEX ™ 71 targeted antifolate 71 trastuzumab DM1 T DM1 71 MKC# MT 71 Voreloxin 71 Metastatic Melanoma 71 intravesical infusion therapy 71 nilotinib Tasigna ® 71 phase IIb clinical 71 rALLy clinical trial 71 RNAi therapeutic targeting 71 hyperphenylalaninemia HPA due 71 Pegloticase 71 Factor Receptor 71 Vicinium TM 71 DURECT proprietary 71 R Saizen R 71 IRX 2 71 Kamada AAT 71 ATRA IV 71 Phase IIb clinical trials 71 XL# XL# 71 CD3 monoclonal antibody 71 Bucindolol 71 seliciclib CYC# 71 oral picoplatin 71 prokinetic agent 71 anti botulism antibody 71 MOVIPREP R 71 Tarceva TM 71 octreotide implant 71 LHRH receptor positive 71 topically applied SEPA 71 Thiarabine 71 Oracea TM 71 anti amnesic 71 erlotinib Tarceva ® 71 formerly LymphoStat B 71 acetonide FA 71 vinorelbine tartrate 71 anticancer compound 71 Telik logo TELINTRA 71 ABL inhibitor 71 agonistic human 71 inhaled formulation 70 Curaxin CBLC# 70 docetaxel Taxotere R 70 FUSILEV ® 70 Gel repository corticotropin injection 70 ELADUR ™ 70 Cloretazine 70 Maribavir 70 oral dihydropyrimidine dehydrogenase DPD 70 targeting CD# 70 Vidaza azacitidine 70 BCG refractory carcinoma 70 Onalta ™ 70 generation PNP inhibitor 70 evaluating tivozanib 70 THR beta agonist 70 nucleoside analog 70 Initiate Phase 70 R sorafenib tablets 70 TKB# 70 ALTROPANE R 70 Pathway Inhibitor 70 Albuferon TM 70 Inhalation Aerosol 70 myelodysplastic myeloproliferative diseases 70 gemcitabine Gemzar ® 70 androgen receptor antagonist 70 psoriasis rheumatoid arthritis 70 bevacizumab Avastin R 70 HCV NS5B polymerase 70 Xcytrin R 70 Spiegelmer ® 70 overactive bladder AA# 70 Angiocept 70 IMA# 70 tyrosine kinase inhibitor TKI 70 Phase Ib clinical trials 70 Pruvel TM 70 dextromethorphan quinidine 70 potently inhibit 70 reversible inhibitor 70 IgG1 monoclonal antibody 70 tiapamil 70 LymphoStat B belimumab 70 Archexin 70 Elagolix 70 Serostim ® 70 KRN# 70 Phase 2b Clinical Trial 70 R roscovitine 70 product platforms AZX# 70 Crofelemer budesonide foam 70 NEBIDO R 70 Aurora kinase inhibitor 70 HDAC Inhibitor 70 peptidic compound 70 triciribine phosphate monohydrate 70 Letairis ambrisentan 70 Initiate Clinical Trial 70 irinotecan doxorubicin oxaliplatin paclitaxel 70 influenza BCX# purine nucleoside 70 MT#/MEDI-# 70 cetuximab Erbitux ® 70 Meets Primary Endpoint 70 Xyfid TM 70 chronic eosinophilic leukemia 70 AKT inhibitor 70 DIFICID ™ 70 Leukine ® 70 Seliciclib 70 resistant hormone refractory 70 topical gel formulation 70 Evoltra ® 70 small molecule thrombopoietin 70 Cerebril TM 70 OvaRex R 70 bucindolol hydrochloride 70 personalized cellular immunotherapy 70 HGS# 70 pathophysiological effects 70 Begins Dosing 70 SinuNase ™ 70 RhuDex ® 70 PRT# 70 candidate REP# 70 generation Hsp# inhibitor 70 non porcine pancreatic 70 mocetinostat MGCD# 70 Aurora Kinase 70 TNF alpha selectively neutralizing 70 evaluating picoplatin 70 CCR5 antagonist 70 hypoxia activated prodrug 70 familial amyloidotic polyneuropathy FAP 70 MKC# MKC# PP 70 mGluR2 positive 70 TRANSDUR ™ 70 acyclovir Lauriad R 70 treat opioid induced 70 novel topoisomerase 70 investigational monoclonal antibody 70 sodium Injection 70 Zemiva ™ 70 potent CYP#A# inhibitors 70 imatinib Gleevec ® 70 rxRNA 70 advanced metastatic renal 70 HCV protease inhibitor 70 rusalatide acetate 70 IMiDs ® compound 70 mild vasodilator 70 hyaluronidase enzyme 70 NPC 1C 70 CCR9 antagonist 70 Traficet EN 70 alfa 2a 70 reslizumab 70 CD# CEA 70 oral ferric iron 70 oral isoform selective HDAC 70 platform HDL Mimetic 70 selective inhibitor 70 sorafenib Nexavar 70 HGS ETR2 70 Solazed ™ 70 Serdaxin ® 70 individualized cellular immunotherapy 70 octreotide acetate 70 TKM ApoB 70 HGS ETR1 mapatumumab 70 evaluating T DM1 70 Presents Positive 70 monoclonal antibody conjugated 69 TRIOLEX HE# APOPTONE HE# 69 Dapagliflozin 69 therapeutic monoclonal antibody 69 JZP 69 Mipomersen 69 Files IND 69 lead molecular radiotherapeutic 69 Squalamine 69 CTAP# Capsules 69 Phase IIb Trial 69 Exelixis compounds 69 FDA APPROVES 69 Zorbtive TM 69 TRANSDUR ® 69 orally inhaled 69 investigational antiplatelet agent 69 candidate XP# 69 inhalation powder 69 docetaxel Taxotere ® 69 vidofludimus 69 N acetylgalactosamine 6 69 Safinamide 69 relapsed leukemia 69 adecatumumab MT# 69 thetreatment 69 mTOR mammalian target 69 ONX 69 Sapacitabine 69 selective orally bioavailable 69 NASH Huntington 69 Immunotherapeutic 69 tumors GIST 69 Temsirolimus 69 inhibitor PPI 69 EVIZON TM 69 Lubiprostone 69 NS5b 69 ELACYT 69 huN# DM1 69 delta gamma agonist 69 transthyretin mediated amyloidosis ATTR 69 injectable formulation 69 treat chronic sinusitis 69 novel synthetic PEGylated 69 MGd 69 metastatic malignant 69 cutaneous T cell 69 PRN FDA Approves 69 Prodarsan R 69 Pruvel ™ 69 compound perifosine 69 Myocet 69 histone deacetylase HDAC inhibitors 69 EZN 69 developing Zerenex TM 69 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 69 initiated Phase Ib 69 corticotropin injection 69 R#/MEM # 69 bevacizumab Avastin ® 69 R lenalidomide 69 Kuvan R 69 SUPPRELIN R LA 69 drug pipeline TAFA# 69 registrational trial 69 JAK inhibitor 69 MEK Inhibitor 69 Soliris TM eculizumab 69 selective inhibition 69 Vicriviroc 69 topical non steroidal 69 HGS ETR1 69 Investigational Treatment 69 Nanobody 69 Liprotamase 69 toenail onychomycosis 69 next generation URAT1 69 castrate resistant prostate cancer 69 Intravenous CP 69 positive allosteric modulator 69 ocular formulation 69 humanized monoclonal 69 ketolide antibiotic 69 immunomodulator 69 Glufosfamide 69 subcutaneous formulation 69 Phase Ib study 69 PEGylated interferon 69 MCSP respectively 69 recurrent glioblastoma multiforme 69 VALSTAR 69 interferon beta 1a infertility 69 systemic juvenile idiopathic 69 nucleotide analog 69 MyVax R 69 depsipeptide 69 Ovitrelle R Serostim 69 relapsed refractory multiple myeloma 69 Phase #/#a trial 69 Cardium Therapeutics TM 69 Chemophase 69 Drug Candidate 69 Pazopanib 69 Delafloxacin 69 EOquin 69 Preclinical studies suggest 69 phosphorylase PNP inhibitor 69 GLP1 INT TM 69 Initiates Phase III 69 RhuDex R 69 volociximab 69 cell carcinoma RCC 69 Genasense ® oblimersen 69 ® lenalidomide 69 Kinase Inhibitor 69 forodesine purine nucleoside phosphorylase 69 Fc fusion protein 69 2 inhibitor CYT# 69 Xeloda ® 69 Azacitidine 69 EVIZON ™ 69 relapsed multiple myeloma 69 CD4 monoclonal antibody 69 mitogen activated ERK kinase 69 Saizen ® 69 Daclizumab 69 trastuzumab Herceptin R 69 II Clinical Trial 69 Proxinium TM 69 PSMA ADC 69 DermaVir Patch 69 Granted Orphan Drug 69 Liposomal 69 ATL/TV# 69 Amigal TM 69 protein tyrosine phosphatase 1B 69 interferon alpha IFN 69 ® bortezomib 69 Simulect 69 mGluR5 NAM 69 Irinotecan 69 Tesetaxel 69 BiovaxID TM 69 humanised monoclonal antibody 69 Auxilium transmucosal film 69 Selective Electrochemical Tumor Ablation 69 KSP inhibitor 69 inflammatory autoimmune diseases 69 somatostatin analogue 69 CDK inhibitor 69 eniluracil 69 beta 1a 69 Augment TM 69 orally dosed 69 immunotherapeutic vaccine 69 pseudobulbar affect PBA 69 small molecule tyrosine 69 Empatic TM 68 inhaled liposomal ciprofloxacin 68 Silodosin 68 HuMax TAC 68 highly selective endothelin 68 metastatic castration resistant 68 antiangiogenesis therapies 68 CBLC# 68 Phase IIb trials 68 proprietary polysaccharide 68 Janus Kinase 68 Troxatyl 68 Zevalin R Ibritumomab 68 NicVAX TM 68 Mg Usa 68 Pralatrexate 68 luteinizing hormone releasing 68 anti secretory 68 Tiuxetan 68 aldehyde dehydrogenase ALDH2 deficiency 68 BENLYSTA TM 68 estrogen receptor antagonist 68 arsenic trioxide injection 68 rHuPH# recombinant human 68 metastatic colorectal 68 Triapine R 68 ELADUR TM 68 cytotoxic conjugate 68 cyclin dependent kinase inhibitor 68 targets Galectin receptors 68 oropharyngeal candidiasis OPC 68 Nexavar ® 68 telomerase therapeutic 68 bladder ovarian 68 Vascular Disrupting Agent 68 highly purified pasteurized 68 non alcoholic steatohepatitis 68 stable nucleic acid 68 NR2B selective 68 ganetespib 68 First Patient Dosed 68 TAFA# 68 Hedgehog Pathway Inhibitor 68 compound ISA# 68 Kit CD# positive 68 selective A2A adenosine receptor 68 long acting muscarinic 68 non nucleoside HCV 68 5 fluorouracil leucovorin 68 Belimumab 68 Pimavanserin 68 Alzhemed TM 68 romidepsin novel 68 novel nucleoside analog 68 receptor modulators 68 investigational oral hepatitis C 68 MEK inhibitors 68 ThermoDox R 68 Bosutinib 68 Vidofludimus 68 Initiates Clinical Trial 68 injectable depot 68 Intravenous Human 68 NS5B polymerase 68 INSPIRE Trial Phase III 68 induced mucositis 68 Deforolimus 68 clinical trials Archexin ® 68 oncolytic 68 markets HP Acthar 68 brivanib 68 catheter occlusion 68 sunitinib Sutent ® 68 Cyclooxygenase Inhibiting Nitric Oxide 68 TOCOSOL Camptothecin 68 oral anti arrhythmic 68 PEG SN# 68 tiuxetan 68 dimebon latrepirdine 68 oral ridaforolimus 68 EGFr expressing metastatic colorectal 68 PDE# 68 targeting Inflammatory Bowel 68 p# inhibitor 68 vascular disrupting agent 68 Vitrasert R 68 PROSTASCINT R 68 Inhalation Solution 68 PSN# [002] 68 Chemokine Receptor 68 * olmesartan medoxomil 68 2A receptor agonist 68 Hematide ™ 68 Pafuramidine 68 product candidate Lpathomab 68 systemically administered 68 novel tubulin binding 68 miconazole Lauriad ® 68 panitumumab Vectibix R 68 M2 subunit 68 isoform selective 68 cortisol synthesis 68 lucinactant 68 MET VEGFR2 68 HCD# [002] 68 MKC# 68 Aviptadil 68 TM Aganocide 68 VISICOL R 68 Panzem ® 68 small molecule glucokinase 68 TLR9 agonist 68 Blinatumomab 68 dihydrochloride Tablets 68 OvaRex ® MAb 68 apoptosis proteins 68 refractory gout 68 GMX# 68 CORT # 68 Presents Preclinical 68 lymphoma CTCL 68 recurrent metastatic ovarian cancer 68 indolent follicular non 68 potent antiproliferative 68 non thiazolidinedione TZD 68 Ribavirin causes 68 Aganocide 68 INTEGRILIN ® 68 non peptidic protease 68 XL# XL# XL# XL# 68 hypoxia inducible factor 68 investigational antibiotic 68 selectively inhibits 68 KNS # 68 rALLy 68 refractory indolent non 68 elotuzumab 68 Pivotal Phase III 68 vascular disrupting agents 68 PrevOnco 68 including eniluracil ADH 68 IV Busulfex 68 ATL# [002] 68 novel oral anticoagulant 68 sodium thiosulfate STS 68 inflammatory PDE 68 LEUKINE 68 Combination REOLYSIN R 68 Apoptone 68 Receives Orphan Drug 68 R metformin Concor 68 Plicera 68 sapacitabine CYC# 68 XP# XP# 68 PHX# 68 Altera Nebulizer System 68 BRIM2 68 SARMs 68 NeoLipid R 68 Phase 2a Clinical Trial 68 substantially excreted 68 opioid induced constipation OIC 68 cisplatin gemcitabine 68 oral transdermal 68 factor G CSF 68 OMP #M# 68 Angiotensin Converting Enzyme 68 cardiometabolic diseases Glucophage 68 Opterone R 68 Solazed 68 Amrubicin 68 poly ADP ribose polymerase 68 Complicated Skin 68 lead Aganocide compound 68 Janus kinase 68 protein kinase inhibitor 68 OncoVEX GM CSF 68 Pharmacokinetics PK 68 Completes Enrollment 68 intravesical instillation 68 orally administered synthetic retinoid 68 plus prednisone prednisolone 68 Nexavar sorafenib 68 romidepsin 68 erlotinib Tarceva R 68 Files Investigational 68 either acutely decompensated 68 Alocrest 68 HCV polymerase 68 ruxolitinib 68 secretory phospholipase A2 68 topical antifungal 68 thiazolides 68 refractory acute myeloid 68 epothilones 68 Onalta 68 certain protein tyrosine 68 Octreolin 68 visilizumab 68 transthyretin TTR 68 angiogenesis inhibitor 68 5 HT2A serotonin 68 FEMALES SHOULD BE ADVISED 68 xanthine oxidase inhibitor 68 allosteric modulator PAM 68 Medoxomil 68 ara C 68 LEP ETU 68 VNP#M 68 oral rivaroxaban 68 Darinaparsin 68 novel therapeutic antibodies 68 metastatic hormone refractory 68 Humanized Anti 68 Tyrima 68 ZEVALIN ® 68 renin inhibitor 68 Pertuzumab 68 RhuDex TM 68 Intermezzo ® zolpidem tartrate 68 vitreoretinal disorders 68 pharmacologically active isomer 68 Disease IBD 68 TRO# 68 motexafin gadolinium Injection 68 Hepatitis C Virus HCV 68 oral dual endothelin 68 Phase 2b Trial 68 apoptosis inducers 68 carcinoma mCRC 68 apoptosis inducer 68 acid phosphatase PAP 68 Potassium Chloride Sodium Ascorbate 68 Gleevec resistant 68 DG# compounds targeting 68 By JENNIFER LEARN 68 Lenalidomide 68 herpetic keratitis 68 Locked Nucleic Acid 68 cancer neuroendocrine tumor 68 Bazedoxifene 68 Seliciclib CYC# 68 RANK Ligand inhibitor 68 DOS# 68 ospemifene 68 anti atherothrombotic 68 Lixivaptan 68 trial evaluating PRX# 68 Diabetic Macular Edema 68 GTC recombinant human 68 PROVENGE sipuleucel T 68 candidate AQ4N 68 carcinoma HCC 68 Application MAA 68 novel immunomodulatory 68 targeting PCSK9 68 Phase 1a clinical 68 Ophena TM 67 maturation inhibitor 67 anti TNF alpha 67 CCX# 67 itraconazole Sporanox 67 YONDELIS 67 pentostatin 67 vaccines oncolytic virus 67 anti PlGF 67 Perflubutane Polymer Microspheres 67 HIV integrase inhibitor 67 hormone refractory metastatic prostate 67 siRNA therapeutic 67 bortezomib Velcade 67 sarcoma melanoma 67 R bisoprolol Euthyrox 67 anthracycline taxane 67 anti CD3 monoclonal 67 Nasdaq VNDA 67 selective phosphodiesterase 67 PF # [002] 67 phase III isavuconazole 67 Talabostat 67 pomalidomide 67 humanized interleukin 6 67 include PLX IBD 67 TOCOSOL 67 corticosteroid dexamethasone 67 irreversible inhibitor 67 epigenetic therapies 67 Atripla combines 67 valopicitabine NM# 67 delta opioid receptor 67 selective agonist 67 Azedra TM 67 Initiates Clinical 67 Tumour Vascular Disrupting Agent 67 OHR/AVR# 67 gefitinib Iressa 67 Zolinza 67 DDP# 67 EGFR TKI 67 Fludara ® 67 basiliximab 67 Epidermal Growth Factor Receptor 67 Phase #b/#a trial 67 Vidaza ® 67 compound INCB# 67 Allovectin 7 67 Lenocta 67 HCV polymerase inhibitors 67 assessing T DM1 67 Zoraxel TM 67 orally inhaled migraine 67 DU #b 67 R bendamustine hydrochloride 67 reversible inhibitors 67 Cloretazine R 67 proprietary transdermal patch 67 AQ4N 67 Prodarsan ® 67 pharmacological chaperone 67 dexamethasone Decadron 67 5 HT6 receptor 67 Injectable Suspension 67 CYT# vascular disrupting 67 Mg Uk 67 Vidaza R 67 ApoB SNALP 67 OncoVex 67 dacetuzumab SGN 67 Anavex #-# 67 Myelofibrosis 67 Fx #A 67 BrachySil TM 67 treat hyperphosphatemia 67 phase IIa clinical 67 Endologix Powerlink System 67 antiangiogenic agent 67 XL# XL# XL# 67 Sphingomab TM 67 Empatic ™ 67 Phase 2a clinical trials 67 D aspartate NMDA receptor 67 POSIDUR TM ELADUR TM 67 generation nucleoside analog 67 Cimzia TM 67 atrial fibrillation budiodarone ATI 67 Dyloject TM 67 anthracycline derivative 67 TRX1 67 human IgG1 monoclonal 67 immunomodulatory therapy 67 unique alkylating agent 67 Actemra tocilizumab 67 severe oral mucositis 67 antibody MT# 67 paclitaxel Taxol ® 67 XmAb ® 67 include Phenoptin TM 67 colorectal bladder 67 apomorphine hydrochloride 67 opioid induced bowel dysfunction 67 VQD 67 Inc. AMEX YMI 67 human C1 inhibitor 67 Orphan Drug designations 67 Phase IIb Clinical Trial 67 candidate NGX 67 tumor vascular disrupting 67 Melphalan 67 GTC recombinant form 67 IMiD 67 EP #R 67 pediatric Crohn disease 67 advanced carcinoid 67 Ofatumumab 67 topoisomerase II inhibitor 67 alefacept 67 Myolimus 67 fumarate 67 prescribed proton pump 67 Recombinant Human 67 NS#/#A protease 67 gastrointestinal stromal 67 Severe Sepsis 67 SAR# [004] 67 novel L DOS# 67 monoclonal antibody IgG1 Mab 67 Advanced Renal Cell 67 Patients Treated With 67 Oral Spray 67 sulfonylhydrazine class 67 Aztreonam lysine 67 selective inverse agonist 67 Relapsed Refractory 67 mitotic kinesins 67 PEG irinotecan 67 small molecule chemotherapeutic 67 QLT# 67 lipoglycopeptide 67 Achieves Primary Endpoint 67 BUPHENYL R 67 KRYSTEXXA TM pegloticase 67 Solution XOPENEX HFA 67 plasma kallikrein inhibitor 67 Application BLA 67 Reports Preclinical Data 67 Bortezomib 67 Ostabolin C TM 67 dihydrochloride 67 epothilone 67 overactive bladder VANTAS R 67 OMNARIS Nasal Spray 67 class mGluR5 inhibitor 67 thrombin component 67 QuadraSphere 67 successfully commercialize Iluvien 67 hematological malignancies 67 ASG 5ME 67 HCl PEPCID ® famotidine 67 riociguat 67 orBec R oral beclomethasone 67 ALK inhibitor 67 Atypical Hemolytic Uremic Syndrome 67 induced macular edema 67 sodium sulfate sodium chloride 67 ThermoDox ® clinical 67 Guanilib 67 non nucleoside 67 Novel Oral 67 Epothilones 67 infectious diseases autoimmune diseases 67 COX Inhibiting Nitric Oxide 67 anti angiogenic agent 67 perifosine novel potentially 67 memantine HCl 67 Perifosine KRX 67 Entereg R 67 Vaccine Adjuvant 67 purpura ITP 67 severe hypercholesterolemia 67 cMET 67 Degarelix 67 oral salmon calcitonin 67 Granulocyte Colony Stimulating Factor 67 Levoleucovorin 67 fosbretabulin 67 Ceflatonin 67 cinacalcet HCl 67 Pivotal Phase 67 Enzastaurin 67 CINTREDEKIN BESUDOTOX 67 PEGylated interferon beta 1a 67 delivered RNAi therapeutic 67 AVAPRO 67 Phase 1b clinical trials 67 inhaled corticosteroid ICS 67 Cleviprex TM clevidipine 67 Maxy G# 67 5 HT4 67 lomitapide 67 ISENTRESS raltegravir 67 immune modulating 67 Novolimus 67 demonstrated antitumor activity 67 generation antisense inhibitor 67 chimeric monoclonal antibody